Related Experiment Videos
Upper gastrointestinal bleeding: etiology and management
N K Arora1, S Ganguly, P Mathur
1Department of Pediatrics, All India Institute of Medical Sciences, New Delhi. nkmanan@hotmail.com
Indian Journal of Pediatrics
|April 4, 2002
Summary
Upper gastrointestinal bleeding in children requires prompt resuscitation and diagnosis via endoscopy. Effective treatments include medications for mucosal lesions and endoscopic therapy or pharmacotherapy for variceal bleeds, with combined beta blockers and sclerotherapy showing best results.
Area of Science:
- Pediatric Gastroenterology
- Critical Care Medicine
- Hepatology
Background:
- Upper gastrointestinal bleeding (UGIB) is a serious condition in children, often caused by mucosal lesions or variceal hemorrhage, particularly in intensive care settings.
- Massive UGIB necessitates immediate resuscitation, including airway management, oxygenation, fluid resuscitation, and blood transfusions.
Purpose of the Study:
- To review the diagnostic and therapeutic strategies for upper gastrointestinal bleeding in children.
- To highlight the need for evidence-based management protocols and outcome predictors in pediatric UGIB.
Main Methods:
- Review of common causes of UGIB in children, including mucosal lesions and varices.
- Discussion of resuscitation measures, diagnostic endoscopy, and treatment options for different bleeding etiologies.
- Examination of risk factors for mortality and rebleeding based on adult studies.
Main Results:
- Upper GI endoscopy is highly effective (85-90%) for diagnosing bleeding sources.
- Treatment varies by cause: antacids, H2-blockers, PPIs, and sucralfate for mucosal lesions; endoscopy, pharmacotherapy, or surgery for variceal bleeds.
- Combination therapy (beta blockers and sclerotherapy) is most effective for variceal bleeds, reducing rebleeding and mortality.
Conclusions:
- Urgent resuscitation and endoscopic diagnosis are critical for managing pediatric upper gastrointestinal bleeding.
- While adult data suggests risk factors for mortality, there's a significant need for pediatric-specific therapeutic trials and outcome predictors.